PGC1α gene Gly482Ser polymorphism predicts improved metabolic, inflammatory and vascular outcomes following bariatric surgery

Abstract

Aims/Hypothesis: Bariatric surgery is currently employed as an effective approach to treat class III obesity and class II obesity with co-morbidities. Unfortunately, the general anthropometric and metabolic outcomes of the surgery are not homogeneous, and defining the eligibility criteria that allow for a more precise prediction of the outcomes of this invasive procedure will refine the selection of patients. Here we tested the hypothesis that the Gly482Ser polymorphism of the ppargc1a gene would predict different outcomes following bariatric surgery. Methods: Fifty-five patients (26 Gly/Gly and 29 Gly/Ser þ Ser/Ser) selected for the Roux-en-Y gastric bypass according to the National Institutes of Health Consensus Statement criteria were followed up for 1 year, monitoring their anthropometric, metabolic and inflammatory parameters. Results: Patients with the Gly482Ser polymorphism had significantly improved reductions in the waist/hip ratio, fasting blood glucose, C-reactive protein, blood leukocyte count, serum interleukin-6 and intima-media thickness of the carotid artery, as compared with Gly/Gly patients. Conclusions/Interpretation: Thus, the Gly482Ser polymorphism may predict a more favorable metabolic and inflammatory outcome for obese patients submitted to bariatric surgery, leading to a reduced atherosclerotic risk.

Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis

“…The PPARGC1A gene was also identified in a search for protein-level interactions with transcripts mapped nearest to T2D susceptibility loci ( Morris et al, 2012 ). Although the rs8192678; G482S Ser482 allele appears to be associated with increased obesity and T2D susceptibility ( Vandenbeek et al, 2017 ) as well as a poorer therapeutic efficacy of rosiglitazone ( Zhang et al, 2010 ), its carriers also appear to respond better to caloric restriction ( Goyenechea et al, 2008 ) and bariatric surgery ( Geloneze et al, 2012 ). In the Boston Puerto Rican Health Study, they found associations between polymorphisms in the PPARGC1A gene and DNA damage, T2D, and CVD ( Lai et al, 2008b ).…”

PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

“…Several studies reported that PPARGC1A rs8192678 was significantly associated with obesity; this polymorphism conferred a higher risk of obesity in certain populations[ 25 , 26 ]. The patients who carried PPARGC1A rs8192678 AA genotype benefited more from interventions aimed at weight loss, including caloric restriction, bariatric surgery, and acarbose treatment[ 27 , 28 ]. The prevalence of lean NAFLD and nonobese NAFLD has increased in eastern and western countries in recent years.…”

Postural Drainage and Manual Lymphatic Drainage for Lower Limb Edema in Women with Morbid Obesity After Bariatric Surgery

“…(4) Five call-up maneuvers were performed on the medial region of the leg; and reabsorption maneuvers, on the same region. (5) The drainage continued with five more call-up maneuvers on the distal region of the leg; and reabsorption maneuvers, on the same region. The thighs and the legs were drained with both hands, through combined maneuvers, with the thumbs placed on the front face.…”